PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
"Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"
- Conditions
- Carcinoma, Renal Cell
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 157
- Registration Number
- NCT03538717
- Locations
- 🇪🇸
Complejo Hospitalario la Mancha Centro, Alcazar de San Juan, Ciudad REAL, Spain
🇪🇸Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain
🇪🇸Hospital Universitario Mutua Terrassa, Terrassa, Barcelona, Spain
A 6-week Study to Evaluate the Safety and Efficacy of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Pfizer
- Registration Number
- NCT03536390
Evaluation of Pharmacokinetic Drug Drug Interaction Between PF-05221304 And PF-06865571 In Healthy Adult Subjects
- Conditions
- Healthy
- Interventions
- Drug: PF-06865571 administered Day 7-14Drug: PF-06865571 administered Day 1-14Drug: PF-05221304 administered Day 1-14Drug: PF-05221304 administered Day 7-14
- First Posted Date
- 2018-05-23
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT03534648
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- Conditions
- LymphomaMultiple MyelomaAcute Myeloid LeukemiaDiffuse Large B-Cell Lymphoma
- Interventions
- Drug: Anti-CD20 Targeting agent
- First Posted Date
- 2018-05-21
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 177
- Registration Number
- NCT03530683
- Locations
- 🇺🇸
LAC+USC Medical Center, Los Angeles, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Northside Hospital, Atlanta, Georgia, United States
A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults
- Conditions
- Respiratory Tract Infections
- Interventions
- Biological: Formulation BBiological: Formulation ABiological: Placebo
- First Posted Date
- 2018-05-18
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1235
- Registration Number
- NCT03529773
- Locations
- 🇺🇸
Meridian Clinical Research, Savannah, Georgia, United States
🇺🇸Meridian Clinical Research Dakota Dunes, Sioux City, Iowa, United States
🇺🇸Aventiv Research Inc., Columbus, Ohio, United States
A Study of PF-06873600 in People With Cancer
- Conditions
- HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
- Interventions
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 155
- Registration Number
- NCT03519178
- Locations
- 🇺🇸
UCLA Hematology/Oncology - Parkside, Santa Monica, California, United States
🇺🇸UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States
🇺🇸University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora, Colorado, United States
2-Week Study In People With Nonalcoholic Fatty Liver Disease
- Conditions
- Non-alcoholic Fatty Liver DiseaseNon-alcoholic Steatohepatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-05-01
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 48
- Registration Number
- NCT03513588
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸High Point Clinical Trials Center, High Point, North Carolina, United States
Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: 13vPnCBiological: Multivalent
- First Posted Date
- 2018-04-30
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 460
- Registration Number
- NCT03512288
- Locations
- 🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States
🇺🇸Cincinnati Children's Medical Center, Cincinnati, Ohio, United States
🇺🇸Pediatric Associates of Mt. Carmel, Inc., Cincinnati, Ohio, United States
Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 270
- Registration Number
- NCT03502616
- Locations
- 🇨🇦
G.R.M.O. (Groupe de recherche en maladies osseuses) Inc., Quebec, Canada
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
- First Posted Date
- 2018-04-17
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 61
- Registration Number
- NCT03499353
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers, Thornton, Colorado, United States
🇺🇸Grady Health System, Atlanta, Georgia, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States